Skip to main content
SpringerLink
Log in

Breast Cancer

  • Chapter
  • First Online:
Side Effects of Medical Cancer Therapy

Abstract

The appropriate selection of medical therapeutic interventions in breast cancer patients is a daily challenge for medical oncologists and takes into account disease characteristics such as stage at diagnosis, age and menopausal status, aggressiveness of the disease, and presence or absence of key therapeutic targets such as hormonal receptors and HER2. Knowledge of treatment-related toxicities as well as patient’s comorbidities, preferences, age, and so on is a critical component of an optimal estimation of the benefit versus harm ratio of a specific therapy.

This chapter reviews the side effects of the four main medical treatment modalities for breast cancer: chemotherapy, ­endocrine therapy, biologic agents, and bone-modifying therapeutics in terms of frequency, monitoring, and practical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5:65–71.

    Article  PubMed  CAS  Google Scholar 

  2. Tannock IF, Hill RP, Bristow RG, Harrington L. The basic science of ­oncology. 4th ed. New York: McGraw-Hill Medical Publishing Division; 2005.

    Google Scholar 

  3. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 suppl 3:1–7.

    Article  PubMed  CAS  Google Scholar 

  4. Takimoto CH, Calvo E. Principles of oncologic pharmacotherapy. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, editors. Cancer management: a multidisciplinary approach. 11th ed. Lawrence: CMPMedica LLC; 2008.

    Google Scholar 

  5. Taxol package insert. http://packageinserts.bms.com/pi/pi_taxol.pdf. Accessed on Sep 2012.

  6. Taxotere package insert. http://products.sanofi.us/taxotere/taxotere.html. Accessed on Sep 2012.

  7. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol. 1997;15:3149–55.

    PubMed  CAS  Google Scholar 

  8. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–7.

    Article  PubMed  CAS  Google Scholar 

  9. Abraxane package insert. http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf. Accessed on Sep 2012.

  10. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

    Article  PubMed  CAS  Google Scholar 

  11. Ixempra package insert. http://packageinserts.bms.com/pi/pi_ixempra.pdf. Accessed on Sep 2012.

  12. Eribulin package insert. http://us.eisai.com/pdf_files/HalavenPI.pdf. Accessed on Sep 2012.

  13. Navelbine package insert. http://www2.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf. Accessed on Sep 2012.

  14. Rouzaud P, Estivals M, Pujazon MC, Carles P, Lauque D, et al. Respiratory complications of the vinorelbine-mitomycin combination. Rev Mal Respir. 1999;16:81–4.

    PubMed  CAS  Google Scholar 

  15. Goli AK, Osman MN, Koduri M, Byrd RP, Roy TM, et al. A case report of vinorelbine monotherapy-related acute bronchospasm and non-ST elevation acute coronary syndrome. Tenn Med. 2011;104:47–8.

    PubMed  Google Scholar 

  16. Gregory RK, Smith IE. Vinorelbine: a clinical review. Br J Cancer. 2000;82:1907–13.

    Article  PubMed  CAS  Google Scholar 

  17. Adriamycin package insert. http://www.pfizer.ca/en/our_products/products/monograph/150. Accessed on Sep 2012.

  18. Ellence package insert. http://labeling.pfizer.com/ShowLabeling.aspx?id=657. Accessed on Sep 2012.

  19. Doxil package insert. http://www.doxil.com/assets/DOXIL_PI_Booklet.pdf. Accessed on Sep 2012.

  20. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004;31:53–90.

    Article  PubMed  CAS  Google Scholar 

  21. European Medicines Agency. Myocet summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000297/WC500031811.pdf. Accessed on Sep 2012.

  22. Fluorouracil package insert. http://hemonc.org/docs/packageinsert/fluorouracil.pdf. Accessed on Sep 2012.

  23. Xeloda package insert. http://www.gene.com/gene/products/information/xeloda/pdf/pi.pdf. Accessed on Sep 2012.

  24. Gemzar package insert. http://pi.lilly.com/us/gemzar.pdf. Accessed on Sep 2012.

  25. Pfizer. Methotrexate product monograph. http://www.pfizer.ca/en/our_products/products/monograph/280. Accessed on Sep 2012.

  26. Qin D, Ma J, Xiao J, Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol. 1997;20:263–5.

    Article  PubMed  CAS  Google Scholar 

  27. Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest. 2003;123:2150–3.

    Article  PubMed  Google Scholar 

  28. Cytoxan package insert. http://packageinserts.bms.com/pi/pi_cytoxan.pdf. Accessed on Sep 2012.

  29. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993;53:5629–37.

    PubMed  CAS  Google Scholar 

  30. Paraplatin package insert. http://packageinserts.bms.com/pi/pi_paraplatin.pdf. Accessed on Sep 2012.

  31. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and Docetaxel chemotherapy for node positive breast cancer patients. The FNCLCC PACS 01 trial. J Clin Oncol. 2006;24(36):5664–71.

    Article  PubMed  CAS  Google Scholar 

  32. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103–9.

    PubMed  CAS  Google Scholar 

  33. Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer. 2011;19 suppl 1:S43–7.

    Article  PubMed  Google Scholar 

  34. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17.

    Article  PubMed  CAS  Google Scholar 

  35. Pace A, Carpano S, Galie E, Savarese A, Della Giulia M, Aschelter A, et al. Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity. J Clin Oncol. 2007;25(18S) (June 20 Suppl). ASCO annual meeting proceedings (post-meeting edition):9114.

    Google Scholar 

  36. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007;12(3):312–9.

    Article  PubMed  CAS  Google Scholar 

  37. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a doubleblind, randomised trial. Ann Oncol. 1997;8(6):569–73.

    Article  PubMed  CAS  Google Scholar 

  38. Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol. 2008 ASCO annual meeting proceedings [Abstract 4009].

    Google Scholar 

  39. Schneider BP, Li L, Muller K, Flockhard D, Radovich M, Hancock BA, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol. 2011;29:80s (suppl; abstr 1000).

    Google Scholar 

  40. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79.

    Article  PubMed  CAS  Google Scholar 

  41. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20(5):816–27.

    Article  PubMed  CAS  Google Scholar 

  42. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med. 1979;91:710–7.

    Google Scholar 

  43. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the Trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.

    Article  PubMed  CAS  Google Scholar 

  44. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol. 1998;25:525–37.

    PubMed  CAS  Google Scholar 

  45. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–32.

    PubMed  CAS  Google Scholar 

  46. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–45.

    Article  PubMed  CAS  Google Scholar 

  47. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–9.

    PubMed  CAS  Google Scholar 

  48. O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9.

    Article  PubMed  Google Scholar 

  49. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Clin Oncol. 2001;19(5):1444–54.

    CAS  Google Scholar 

  50. 3rd Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson Jr JA, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918.

    Article  PubMed  CAS  Google Scholar 

  51. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage. 2000;19:118–29.

    Article  PubMed  CAS  Google Scholar 

  52. Almer KR, Corbett CL, Holdsworth CD. Double-blind crossover study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980;79:1272–5.

    Google Scholar 

  53. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou VV, Kalofonos HP. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist. 1998;3:50–3.

    PubMed  CAS  Google Scholar 

  54. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531–8.

    Article  PubMed  Google Scholar 

  55. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100 suppl 9:2026–46.

    Article  PubMed  Google Scholar 

  56. Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998;83:1433–9.

    Article  PubMed  CAS  Google Scholar 

  57. Peterson DE, Petit RG. Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. Proc Am Soc Clin Oncol. 2004;22:731 (abstr).

    Google Scholar 

  58. Hejna M, Kostler W, Raderer M, Steger GG, Brodowicz T, Scheithauer W, et al. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM- CSF: results of a prospective randomized trial. Eur J Cancer. 2001;37:1994–2002.

    Article  PubMed  CAS  Google Scholar 

  59. Gorzegno G, Cerutti S, Sperone P, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) mouthwash on grade III chemotherapy-induced oral mucositis. Proc Am Soc Clin Oncol. 1999;18:584a.

    Google Scholar 

  60. Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, et al. Phase I study of transforming growth factor-beta 3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999;5:1363–8.

    PubMed  CAS  Google Scholar 

  61. Bjordal JM, Bensadoun RJ, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19(8):1069–77.

    Article  PubMed  Google Scholar 

  62. Falleti MG, Sanflippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.

    Article  PubMed  Google Scholar 

  63. Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived cognitive problems reflect? J Support Oncol. 2008;6:238–42.

    PubMed  Google Scholar 

  64. Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH. Cognitive dysfunction and subjective complaints of cancer patients: a cross sectional study in a cancer rehabilitation centre. Eur J Cancer. 2004;40:43–9.

    Article  PubMed  CAS  Google Scholar 

  65. Meyers CA. How chemotherapy damages the central nervous system. J Biol. 2008;7:11.

    Article  PubMed  CAS  Google Scholar 

  66. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard dose systemic chemotherapy in long term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.

    Article  PubMed  CAS  Google Scholar 

  67. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-flurouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7:12.

    Article  PubMed  CAS  Google Scholar 

  68. Kreukels BP, Hamburger HL, de Ruiter MB, van Dam FS, Ridderinkhof KR, Boogerd W, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol. 2008;119:533–41.

    Article  PubMed  Google Scholar 

  69. Schover LR, Yetman RJ, Tuason LJ. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer. 1995;75:54–64.

    Article  PubMed  CAS  Google Scholar 

  70. Wilmoth MC, Ross JA. Women’s perception: breast cancer treatment and sexuality. Cancer Pract. 1997;5:353–9.

    PubMed  CAS  Google Scholar 

  71. Bakewell RT, Volker DL. Sexual dysfunction related to the treatment of young women with breast cancer. Clin J Oncol Nurs. 2005;9:697–702.

    Article  PubMed  Google Scholar 

  72. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology. 2004;13(5):295–308.

    Article  PubMed  Google Scholar 

  73. Goldfarb SB, Dickler M, Sit L, et al. Sexual dysfunction in women with breast cancer: prevalence and severity. J Clin Oncol. 2009;27(15s):Abstract 9558.

    Google Scholar 

  74. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83.

    Article  PubMed  Google Scholar 

  75. Pedersen-Bjergaard J, Sigsgaard TC, Nielson D, Gjedde SB, Philip P, Hansen M, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosomal translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol. 1992;10:1444–51.

    PubMed  CAS  Google Scholar 

  76. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179–91.

    Article  PubMed  CAS  Google Scholar 

  77. Peto R, Davies C. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women – preliminary results. Breast Cancer Res Treat. 2007;106(suppl 1):Abstract 48.

    Google Scholar 

  78. Gray RG, Rea DW, Handley K, et al. aTTom (adjuvant Tamoxifen – to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer – preliminary results. J Clin Oncol. 2008;26(suppl):10s:Abstract 513.

    Google Scholar 

  79. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM Phase III Trial Comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol. 2010;28:4594–600.

    Article  PubMed  CAS  Google Scholar 

  80. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early – stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–43.

    Google Scholar 

  81. The BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–76.

    Google Scholar 

  82. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007;369:559–70.

    Article  PubMed  CAS  Google Scholar 

  83. van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet. 2011;377:321–31.

    Article  PubMed  CAS  Google Scholar 

  84. Goss PE, Ingle JN, Chapman J-AW, et al. Final analysis of NCIC CTG MA.27: a randomized phase iii trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer (abstr. S1-1). In 33th annual San Antonio breast cancer symposium, San Antonio, 8–12 Dec 2010.

    Google Scholar 

  85. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–13.

    Article  PubMed  CAS  Google Scholar 

  86. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.

    Article  PubMed  CAS  Google Scholar 

  87. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–8.

    Article  PubMed  CAS  Google Scholar 

  88. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 336: Tamoxifen and uterine cancer. Obstet Gynecolol. 2006;107:1475–8.

    Google Scholar 

  89. Gerber B, Krause A, Muller H, Reimer T, Külz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464–70.

    PubMed  CAS  Google Scholar 

  90. Neri F, Maggiano T. Surveillance of endometrial pathologies especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol. 2009;30:357–60.

    PubMed  CAS  Google Scholar 

  91. Garber JE, Halabi S, Tolaney SM. Factor V Leyden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102:942–9.

    Article  PubMed  CAS  Google Scholar 

  92. Boekhout AH, Vincent AD, Dalesio OB. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double blind, placebo-controlled trial. J Clin Oncol. 2011;29:3862–8.

    Article  PubMed  CAS  Google Scholar 

  93. Fisher B, Constantiono JP, Wickerham L, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652–62.

    Article  PubMed  CAS  Google Scholar 

  94. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, et al. Clear evidence that long-term, low-dose tamoxifen can induce ­ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69:2961–4.

    Article  PubMed  CAS  Google Scholar 

  95. Dent SF, Gaspo R, Kissner G, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011;126:295–310.

    Article  PubMed  CAS  Google Scholar 

  96. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–57.

    Article  PubMed  CAS  Google Scholar 

  97. Body JJ. Prevention and treatment of side effects of systemic treatment: bone loss. Ann Oncol. 2010;21 suppl 7:vii180–5.

    Article  PubMed  Google Scholar 

  98. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118:81–7.

    Article  PubMed  CAS  Google Scholar 

  99. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.

    Article  PubMed  CAS  Google Scholar 

  100. Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010;19:388–95.

    Article  PubMed  Google Scholar 

  101. Schilder CM, Seynaeve C, Beex WB, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of post-menopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1249–300.

    Article  CAS  Google Scholar 

  102. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26(4 suppl 12):60–70.

    PubMed  CAS  Google Scholar 

  103. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  104. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.

    Article  PubMed  CAS  Google Scholar 

  105. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Herceptin Adjuvant (HERA) Trial Study Team, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  PubMed  CAS  Google Scholar 

  106. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20.

    Google Scholar 

  107. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491–7.

    Article  PubMed  CAS  Google Scholar 

  108. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Google Scholar 

  109. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

    Article  PubMed  CAS  Google Scholar 

  110. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  PubMed  CAS  Google Scholar 

  111. Friedländer E, Barok M, Szöllosi J, Vereb G. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett. 2008;116(2):126–40.

    Article  PubMed  CAS  Google Scholar 

  112. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698–704.

    Article  PubMed  CAS  Google Scholar 

  113. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301–7.

    Article  PubMed  CAS  Google Scholar 

  114. Shih J, Yang C, Su W, et al. A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). J Clin Oncol. 2009;27(suppl; abstr 8013):15s.

    Google Scholar 

  115. Yang C, Shih J, Su W, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol. 2010;28(suppl; abstr 7521):15s.

    Google Scholar 

  116. Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res. 2009;69(24 suppl):5060.

    Google Scholar 

  117. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30.

    Article  PubMed  CAS  Google Scholar 

  118. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. for the CLEOPATRA study group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. doi:10.1056NEJMoa1113216. Epub 2011 Dec 7.

    Google Scholar 

  119. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57(5):963–9.

    PubMed  CAS  Google Scholar 

  120. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    Article  PubMed  CAS  Google Scholar 

  121. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–47.

    Article  PubMed  CAS  Google Scholar 

  122. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–9.

    Article  PubMed  CAS  Google Scholar 

  123. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.

    Article  PubMed  CAS  Google Scholar 

  124. Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, et al. RIBBON-2: a randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res. 2009;69(suppl. 3; abstr 42):495s.

    Google Scholar 

  125. Hamilton EP, Blackwell KL. Safety of bevacizumab in patients with metastatic breast cancer. Oncology. 2011;80(5–6):314–25.

    Article  PubMed  CAS  Google Scholar 

  126. Avastin (bevacizumab) [prescribing information]. South San Francisco: Genentech; 2011.

    Google Scholar 

  127. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension. 2003;42(6):1206–52.

    Google Scholar 

  128. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465–77.

    Article  PubMed  CAS  Google Scholar 

  129. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269–78.

    Article  PubMed  CAS  Google Scholar 

  130. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10(3):355–60.

    Article  PubMed  Google Scholar 

  131. Hambleton J, Skillings J, Kabbinavar F, Bergsland E, Holmgren E, Holden SN, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2005;23(16s):3554. ASCO annual meeting proceedings. Part I of II (June 1 suppl).

    Google Scholar 

  132. Dirix LY, Romieu G, Provencher L, Grimes D, de Souzo VL, Paterson A, et al. Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Cancer Res. 2009;69(suppl 2; abstr 4116):292s.

    Google Scholar 

  133. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9.

    Article  PubMed  Google Scholar 

  134. Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. 2009;9(7):999–1007.

    Article  PubMed  CAS  Google Scholar 

  135. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632–8.

    Article  PubMed  CAS  Google Scholar 

  136. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3–15.

    Article  PubMed  Google Scholar 

  137. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat. 2010;122(1):189–91.

    Article  PubMed  Google Scholar 

  138. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive ­metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.

    Article  PubMed  CAS  Google Scholar 

  139. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.

    PubMed  CAS  Google Scholar 

  140. Boxed WARNINGS and Additional Important Safety Information. http://www.herceptin.com/hcp/. Accessed on Nov 2011.

  141. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–32.

    Article  PubMed  CAS  Google Scholar 

  142. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012;23(3):791–800. Epub 2011 Jun 10.

    Article  PubMed  CAS  Google Scholar 

  143. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–44.

    Article  PubMed  CAS  Google Scholar 

  144. Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131–7.

    Article  PubMed  CAS  Google Scholar 

  145. Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.

    Article  PubMed  CAS  Google Scholar 

  146. Chatsiproios D, Haidinger R, Suter T. Practical management recommendations for anti-ErbB2 therapy with lapatinib. Breast Care (Basel). 2008;3(s1):13–6.

    Article  Google Scholar 

  147. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–65.

    Article  PubMed  CAS  Google Scholar 

  148. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667–73.

    Article  PubMed  CAS  Google Scholar 

  149. Moy B, Rappold E, Williams L, et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol. 2009;27(suppl; abstr 1043):15s.

    Google Scholar 

  150. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86.

    PubMed  Google Scholar 

  151. Neratinib trials investigator file.

    Google Scholar 

  152. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859–65.

    Article  PubMed  CAS  Google Scholar 

  153. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684–92.

    Article  PubMed  CAS  Google Scholar 

  154. Russell SD, Blackwell KL, Lawrence J, Pippen Jr JE, Roe MT, Wood F, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416–21.

    Article  PubMed  CAS  Google Scholar 

  155. Azim H, Azim Jr HA, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 2009;35(7):633–8.

    Article  PubMed  CAS  Google Scholar 

  156. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA. 2001;98(10):5780–5.

    Article  PubMed  CAS  Google Scholar 

  157. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–95.

    Article  PubMed  CAS  Google Scholar 

  158. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Colangelo LH, Lopa SH, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27(20):3385–90.

    Article  PubMed  CAS  Google Scholar 

  159. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999–3005.

    Article  PubMed  CAS  Google Scholar 

  160. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010;78(4):693–703.

    Article  PubMed  CAS  Google Scholar 

  161. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268–78.

    Article  PubMed  CAS  Google Scholar 

  162. Uribe JM, Keely SJ, Traynor-Kaplan AE, Barrett KE. Phosphatidylinositol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion. J Biol Chem. 1996;271(43):26588–95.

    Article  PubMed  CAS  Google Scholar 

  163. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15(7):2552–8.

    Article  PubMed  CAS  Google Scholar 

  164. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169–76.

    Article  PubMed  CAS  Google Scholar 

  165. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–12.

    Article  PubMed  CAS  Google Scholar 

  166. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23(22):5235–46.

    Article  PubMed  Google Scholar 

  167. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–58.

    Article  PubMed  CAS  Google Scholar 

  168. Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20(20):4271–2.

    Article  PubMed  CAS  Google Scholar 

  169. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J. 2007;14(3):167–70.

    PubMed  Google Scholar 

  170. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer. 2007;7:150.

    Article  PubMed  CAS  Google Scholar 

  171. Chang SC, Chang CY, Chen CY, Yu CJ. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol. 2010;5(7):1105–6.

    Article  PubMed  Google Scholar 

  172. Kuo LC, Lin PC, Wang KF, Yuan MK, Chang SC. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 2011;28(1):79–82.

    Article  PubMed  Google Scholar 

  173. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004;18(3):645–6.

    Article  PubMed  CAS  Google Scholar 

  174. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol. 2010;21(3):474–80.

    Article  PubMed  CAS  Google Scholar 

  175. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965–72.

    Article  PubMed  CAS  Google Scholar 

  176. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zolendronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41.

    Article  PubMed  CAS  Google Scholar 

  177. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zolendronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-months results of the ZO-FAST study. Ann Oncol. 2010;21:2188–94.

    Article  PubMed  CAS  Google Scholar 

  178. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al.; AZURE Investigators. Breast-cancer adjuvant therapy with zolendronic acid. N Engl J Med. 2011;365(15):1396–405.

    Google Scholar 

  179. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  PubMed  CAS  Google Scholar 

  180. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.

    Article  PubMed  CAS  Google Scholar 

  181. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. J Clin Oncol. 2010;28(35):5132–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium

    Philippe G. Aftimos M.D., Andrea Gombos M.D. & Lina Pugliano M.D., B.Sc. (Hons), M.B.B.S., FRACP

  2. Medical Oncology Department, Institut Jules Bordet, Brussels, Belgium

    Ahmad Awada M.D., Ph.D.

  3. Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

    Martine J. Piccart M.D., Ph.D.

Authors
  1. Philippe G. Aftimos M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Gombos M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lina Pugliano M.D., B.Sc. (Hons), M.B.B.S., FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmad Awada M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martine J. Piccart M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Rue Barble 4, Luxembourg, 1210, Luxembourg

    Mario A. Dicato

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Aftimos, P.G., Gombos, A., Pugliano, L., Awada, A., Piccart, M.J. (2013). Breast Cancer. In: Dicato, M. (eds) Side Effects of Medical Cancer Therapy. Springer, London. https://doi.org/10.1007/978-0-85729-787-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-787-7_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-786-0

  • Online ISBN: 978-0-85729-787-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation